Effects of alendronate sodium versus hormone replacement therapy for osteoporosis

doi:10.3969/j.issn.2095-4344.2016.46.007

Abstract

Abstract:

BACKGROUND: Estrogen, bisphosphonates, and calcitonin have been shown to improve bone density and decrease fracture rate, among which, alendronate sodium is the most commonly used and gains extensive attention.
OBJECTIVE: To compare the treatment outcomes of alendronate sodium and hormone replacement therapies for postmenopausal osteoporosis.
METHODS: 198 cases of postmenopausal osteoporosis were randomly divided into two groups (n=99 per group), and then respectively given the oral administration of alendronate sodium, 70 mg weekly, continuous for 1 year, and the oral treatment of tibolone tablets (hormone replacement therapy group),
2.5 mg/d, for 1 consecutive year. The bone density and sex hormone levels before and after treatment, the incidence of adverse reactions and the levels of bone turnover makers were compared between two groups. Furthermore, visual analogue scale scores were detected.
RESULTS AND CONSLUSION: The bone densities of the femoral neck and L1-4 were significantly improved in both groups after treatment (P < 0.05). The hormone replacement therapy significantly decreased the serum levels of estradiol and progesterone, and significantly increased the cortisol level (P < 0.05). The visual analogue scale scores in the alendronate sodium group were significantly superior to those in the hormone replacement therapy group (P < 0.05). Alendronate sodium significantly decreased serum levels of procollagen type I N-terminal peptide and C-terminal cross-linking telopeptide of type I collagen, as well as significantly increased alkaline phosphatase and osteocalcin compared with the hormone replacement therapy (P < 0.05). The incidence of adverse reactions, such as nausea and fatigue, in the hormone replacement therapy group was higher than that in the alendronate sodium group (P < 0.05). These results suggest that alendronate sodium and hormone replacement therapies both can markedly improve the bone density and promote osteogenesis; in contrast, alendronate sodium exerts little influence on hormone levels and slight adverse reactions, achieving better treatment outcomes.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Hormone Replacement Therapy, Postmenopause, Osteoporosis, Bone Density, Tissue Engineering

CLC Number:

R318

Su Fan, Lin Jing-xia, Wu Li-qiu, Cai Dong-mei, Zhuang Ze. Effects of alendronate sodium versus hormone replacement therapy for osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(46): 6893-6898.

Figures/Tables 2

References

[1] Suri P,Morgenroth DC,Hunter DJ.Epidemiology of Osteoarthritis and Associated Comorbidities.PMR. 2012;4(5):S10-19.
[2] Chopin F, Biver E, Funck-Brentano T,et al.Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis.Joint Bone Spine. 2012;79(1):26-31.
[3] Castañeda S, Roman-Blas JA, Largo R, et al.Subchondral bone as a key target for osteoarthritis treatment. Biochemical Pharmacology.2012;83(3): 315-323.
[4] Cox G,Einhorn TA,Tzioupis C,et al.Bone-turnover markers in fracture healing.J Bone Joint Surg Br.2010; 92(3):329-334.
[5] Ramonda R,Lorenzin M,Modesti V.Serological markers of erosive hand osteoarthritis.Eur J Intl Med. 2013; 24(1): 11-15.
[6] 刘忠厚,杨定焯,朱汉民,等.中国人骨质疏松症建议诊断标准(第2稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[7] Rousseau JCH,Garnero P.Biological markers in osteoarthritis.Bone.2012;51(2):265-277.
[8] Zhang Y,Joanne M.Epidemiology of Osteoarthritis.Clin Geriatr Med N Am.2010;26(3): 355-369.
[9] Patra D,Sandell LJ.Recent advances in biomarkers in osteoarthritis.Curr Opin Rheumatol.2011;23(5): 465-470.
[10] White HD, Ahmad AM, Durham BH, et al. Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency. J Clin Endocrinol Metab. 2011；96(3):726-736.
[11] Karsdal MA,Byrjalsen I,Bay-Jensen AC,et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis-the effect of sex, Kellgren-Lawrence(KL)score,Body Mass Index(BMI),oral salmon calcitonin(sCT) treatment and diurnal variation.BMC Musculoskeletal Disorders. 2010;11:125.
[12] Fait T, Donat J, Jenicek J, et al. Recommendation for hormone replacement therapy in postmenopause. Ceska gynekologie. 2010;75(2):109-110.
[13] Patra D,Sandell LJ.Recent advances in biomarkers in osteoarthritis.Curr Opin Rheumatol.2011;23(5): 465-470.
[14] Martínez J,Olmos JM,Hernández JL,et al.Bone turnover markers in Spanish postmenopausal women： The Camargo cohort study.Clin Chim Acta.2009; 409(1-2):70-74.
[15] Cortes-Prieto J, Vicente-Hernanz ML, Cortes-Garcia A, et al. Hormone replacement therapy: evolution of body mass index, bone mineral density, and lipid profile. Horm Mol Biol Clin Investig. 2013;13(2):19-40.
[16] Bay-Jensen AC,Slagboom E,Chen-An P,et al.Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis.Menopause.2013; 20(5):578-586.
[17] Eriksen EF. Hormone replacement therapy or SERMS in the long term treatment of osteoporosis. Minerva ginecologica. 2012;64(3):207-221.
[18] 杨辉,唐三元,詹鹏.骨密度结合singh指数预测老年髋部骨折风险的意义[J].中国矫形外科杂志,2012,10: 900-902.
[19] Ragnar Agnarsson H, Johannsson G, Ragnarsson O. The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy. J Clin Endocrinol Metab.2014;99(4): 1479-1485.
[20] Stewart A,Black A,Robins SP,et al.Bone density and bone turnover in patients with osteoarthritis and osteoporosis.J Rheumatol.1999;26(3):622-626.
[21] Maichuk E, Voevodina IV, Mitrokhina TV, et al. The risk of atherosclerosis and osteoporosis development in post-ovariectomy syndrome women during hormone replacement therapy. Terapevticheskii arkhiv. 2014; 86(8):75-79.
[22] Karsdal MA,Byrjalsen I,Bay-Jensen AC,et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis-the effect of sex, Kellgren-Lawrence(KL)score,Body Mass Index(BMI),oral salmon calcitonin(sCT) treatment and diurnal variation.BMC Musculoskeletal Disorders. 2010; 11:125.
[23] Cartwright B, Robinson J, Seed PT,et al. Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density. J Clin Endocrinol Metab. 2016; 101(9):3497-3505.
[24] Puntus T,Schneider B,Meran J,et al.Influence of age and gender on associations of body mass index with bone mineral density,bone turnover markers and circulating calcium-regulating and bone-active sex hormones.Bone.2011;49(4):824-829.
[25] Evola G, Novo G, Amoroso G, et al. Modification of the lipidic and coagulative pattern in postmenopause women: effect of hormone replacement therapy. International angiology. 2010;29(4):355-361.
[26] Chopin F,Biver E,Funck-Brentano T.Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis.Joint Bone Spine. 2012; 79(1):26-31.
[27] Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Przeglad Menopauzalny. 2014;13(4): 213-220.